array(40) {
  [0]=>
  string(4) "8558"
  ["article_id"]=>
  string(4) "8558"
  [1]=>
  string(93) "Sanofi and Translate Bio Collaborate to Develop Novel mRNA Vaccine Candidate Against COVID-19"
  ["article_title"]=>
  string(93) "Sanofi and Translate Bio Collaborate to Develop Novel mRNA Vaccine Candidate Against COVID-19"
  [2]=>
  string(150) "PARIS and LEXINGTON, MASS. - March 27, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO)"
  ["short_description"]=>
  string(150) "PARIS and LEXINGTON, MASS. - March 27, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO)"
  [3]=>
  string(250) "PARIS and LEXINGTON, MASS. - March 27, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, will collaborate to develop a novel..."
  ["description"]=>
  string(250) "PARIS and LEXINGTON, MASS. - March 27, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, will collaborate to develop a novel..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(272) "https://www.drugs.com/clinical_trials/sanofi-translate-bio-collaborate-develop-novel-mrna-vaccine-candidate-against-covid-19-18497.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sanofi+and+Translate+Bio+Collaborate+to+Develop+Novel+mRNA+Vaccine+Candidate+Against+COVID-19"
  ["blog_url"]=>
  string(272) "https://www.drugs.com/clinical_trials/sanofi-translate-bio-collaborate-develop-novel-mrna-vaccine-candidate-against-covid-19-18497.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sanofi+and+Translate+Bio+Collaborate+to+Develop+Novel+mRNA+Vaccine+Candidate+Against+COVID-19"
  [15]=>
  string(19) "2020-03-27 09:03:02"
  ["add_date"]=>
  string(19) "2020-03-27 09:03:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8665"
  ["article_id"]=>
  string(4) "8665"
  [1]=>
  string(50) "Akcea Therapeutics Promotes Damien McDevitt to CEO"
  ["article_title"]=>
  string(50) "Akcea Therapeutics Promotes Damien McDevitt to CEO"
  [2]=>
  string(154) "Akcea Therapeutics (NASDAQ: AKCA) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company̵"
  ["short_description"]=>
  string(154) "Akcea Therapeutics (NASDAQ: AKCA) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company̵"
  [3]=>
  string(408) "Akcea Therapeutics (NASDAQ: AKCA) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company’s interim CEO since September 2019, when CEO Paula Soteropoulos, president Sarah Boyce, and chief operating officer Jeff Goldberg left in a sudden management shakeup. Akcea is advancing a group of experimental rare disease drugs discovered by […]"
  ["description"]=>
  string(408) "Akcea Therapeutics (NASDAQ: AKCA) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company’s interim CEO since September 2019, when CEO Paula Soteropoulos, president Sarah Boyce, and chief operating officer Jeff Goldberg left in a sudden management shakeup. Akcea is advancing a group of experimental rare disease drugs discovered by […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(89) "https://xconomy.com/boston/2020/03/26/akcea-therapeutics-promotes-damien-mcdevitt-to-ceo/"
  ["blog_url"]=>
  string(89) "https://xconomy.com/boston/2020/03/26/akcea-therapeutics-promotes-damien-mcdevitt-to-ceo/"
  [15]=>
  string(19) "2020-03-27 08:56:35"
  ["add_date"]=>
  string(19) "2020-03-27 08:56:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8666"
  ["article_id"]=>
  string(4) "8666"
  [1]=>
  string(71) "Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections"
  ["article_title"]=>
  string(71) "Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections"
  [2]=>
  string(150) "Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership"
  ["short_description"]=>
  string(150) "Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership"
  [3]=>
  string(387) "Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership announced this week gives the Swiss pharmaceutical giant the option to license the antibiotic from San Diego-based Forge. The preclinical biotech will retain control of the program, FG-LpxC LUNG, until Roche decides whether to […]"
  ["description"]=>
  string(387) "Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership announced this week gives the Swiss pharmaceutical giant the option to license the antibiotic from San Diego-based Forge. The preclinical biotech will retain control of the program, FG-LpxC LUNG, until Roche decides whether to […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(113) "https://xconomy.com/san-diego/2020/03/26/forge-inks-roche-deal-for-antibiotic-aimed-at-drug-resistant-infections/"
  ["blog_url"]=>
  string(113) "https://xconomy.com/san-diego/2020/03/26/forge-inks-roche-deal-for-antibiotic-aimed-at-drug-resistant-infections/"
  [15]=>
  string(19) "2020-03-27 08:13:37"
  ["add_date"]=>
  string(19) "2020-03-27 08:13:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8626"
  ["article_id"]=>
  string(4) "8626"
  [1]=>
  string(50) "Longer lives not dependent on increased energy use"
  ["article_title"]=>
  string(50) "Longer lives not dependent on increased energy use"
  [2]=>
  string(150) "Growing consumption of energy and fossil fuels over four decades did not play a significant role in increasing life expectancy across 70 countries. Ne"
  ["short_description"]=>
  string(150) "Growing consumption of energy and fossil fuels over four decades did not play a significant role in increasing life expectancy across 70 countries. Ne"
  [3]=>
  string(286) "Growing consumption of energy and fossil fuels over four decades did not play a significant role in increasing life expectancy across 70 countries. New research has quantified the importance of different development factors to improvements in physical health on an international scale. "
  ["description"]=>
  string(286) "Growing consumption of energy and fossil fuels over four decades did not play a significant role in increasing life expectancy across 70 countries. New research has quantified the importance of different development factors to improvements in physical health on an international scale. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200326193906.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200326193906.htm"
  [15]=>
  string(19) "2020-03-27 07:39:06"
  ["add_date"]=>
  string(19) "2020-03-27 07:39:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8583"
  ["article_id"]=>
  string(4) "8583"
  [1]=>
  string(62) "China Bans Import and Sale of BMS’ Cancer Drug Abraxane"
  ["article_title"]=>
  string(62) "China Bans Import and Sale of BMS’ Cancer Drug Abraxane"
  [2]=>
  string(163) "&#nl        China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbu"
  ["short_description"]=>
  string(163) "&#nl        China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbu"
  [3]=>
  string(262) "&#nl        China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbuster Abraxane (nanoparticle albumin-bound paclitaxel) following an inspection in the U.S.&#nl      "
  ["description"]=>
  string(262) "&#nl        China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbuster Abraxane (nanoparticle albumin-bound paclitaxel) following an inspection in the U.S.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(94) "https://www.fdanews.com/articles/196407-china-bans-import-and-sale-of-bms-cancer-drug-abraxane"
  ["blog_url"]=>
  string(94) "https://www.fdanews.com/articles/196407-china-bans-import-and-sale-of-bms-cancer-drug-abraxane"
  [15]=>
  string(19) "2020-03-27 06:51:27"
  ["add_date"]=>
  string(19) "2020-03-27 06:51:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8584"
  ["article_id"]=>
  string(4) "8584"
  [1]=>
  string(58) "Bristol-Myers Squibb Delays MS Drug Launch Due to COVID-19"
  ["article_title"]=>
  string(58) "Bristol-Myers Squibb Delays MS Drug Launch Due to COVID-19"
  [2]=>
  string(149) "&#nl        Bristol-Myers Squibb is delaying the launch of its multiple-sclerosis drug Zeposia (ozanimod) because of the COVID-19 pandemic.&#nl      "
  ["short_description"]=>
  string(149) "&#nl        Bristol-Myers Squibb is delaying the launch of its multiple-sclerosis drug Zeposia (ozanimod) because of the COVID-19 pandemic.&#nl      "
  [3]=>
  string(149) "&#nl        Bristol-Myers Squibb is delaying the launch of its multiple-sclerosis drug Zeposia (ozanimod) because of the COVID-19 pandemic.&#nl      "
  ["description"]=>
  string(149) "&#nl        Bristol-Myers Squibb is delaying the launch of its multiple-sclerosis drug Zeposia (ozanimod) because of the COVID-19 pandemic.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(98) "https://www.fdanews.com/articles/196406-bristol-myers-squibb-delays-ms-drug-launch-due-to-covid-19"
  ["blog_url"]=>
  string(98) "https://www.fdanews.com/articles/196406-bristol-myers-squibb-delays-ms-drug-launch-due-to-covid-19"
  [15]=>
  string(19) "2020-03-27 06:50:09"
  ["add_date"]=>
  string(19) "2020-03-27 06:50:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8667"
  ["article_id"]=>
  string(4) "8667"
  [1]=>
  string(66) "With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases"
  ["article_title"]=>
  string(66) "With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases"
  [2]=>
  string(150) "Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year "
  ["short_description"]=>
  string(150) "Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year "
  [3]=>
  string(367) "Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Therapeutics and Menlo Park, CA-based TranscripTx have merged under the ReCode name and leadership of CEO […]"
  ["description"]=>
  string(367) "Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Therapeutics and Menlo Park, CA-based TranscripTx have merged under the ReCode name and leadership of CEO […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(110) "https://xconomy.com/san-francisco/2020/03/26/with-80m-recode-looks-to-advance-rna-therapies-for-lung-diseases/"
  ["blog_url"]=>
  string(110) "https://xconomy.com/san-francisco/2020/03/26/with-80m-recode-looks-to-advance-rna-therapies-for-lung-diseases/"
  [15]=>
  string(19) "2020-03-27 05:55:03"
  ["add_date"]=>
  string(19) "2020-03-27 05:55:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8531"
  ["article_id"]=>
  string(4) "8531"
  [1]=>
  string(73) "FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis"
  ["article_title"]=>
  string(73) "FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis"
  [2]=>
  string(150) "PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Z"
  ["short_description"]=>
  string(150) "PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Z"
  [3]=>
  string(249) "PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis..."
  ["description"]=>
  string(249) "PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(226) "https://www.drugs.com/newdrugs/fda-approves-zeposia-ozanimod-relapsing-forms-multiple-sclerosis-5189.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Zeposia+%28ozanimod%29+for+Relapsing+Forms+of+Multiple+Sclerosis"
  ["blog_url"]=>
  string(226) "https://www.drugs.com/newdrugs/fda-approves-zeposia-ozanimod-relapsing-forms-multiple-sclerosis-5189.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Zeposia+%28ozanimod%29+for+Relapsing+Forms+of+Multiple+Sclerosis"
  [15]=>
  string(19) "2020-03-27 05:03:14"
  ["add_date"]=>
  string(19) "2020-03-27 05:03:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:00"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8627"
  ["article_id"]=>
  string(4) "8627"
  [1]=>
  string(78) "Worldwide scientific collaboration unveils genetic architecture of gray matter"
  ["article_title"]=>
  string(78) "Worldwide scientific collaboration unveils genetic architecture of gray matter"
  [2]=>
  string(150) "For the first time, more 360 scientists from 184 different institutions have contributed to a global effort to find more than 200 regions of the genom"
  ["short_description"]=>
  string(150) "For the first time, more 360 scientists from 184 different institutions have contributed to a global effort to find more than 200 regions of the genom"
  [3]=>
  string(323) "For the first time, more 360 scientists from 184 different institutions have contributed to a global effort to find more than 200 regions of the genome and more than 300 specific genetic variations that affect the structure of the cerebral cortex and likely play important roles in psychiatric and neurological conditions. "
  ["description"]=>
  string(323) "For the first time, more 360 scientists from 184 different institutions have contributed to a global effort to find more than 200 regions of the genome and more than 300 specific genetic variations that affect the structure of the cerebral cortex and likely play important roles in psychiatric and neurological conditions. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200326160801.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200326160801.htm"
  [15]=>
  string(19) "2020-03-27 04:08:01"
  ["add_date"]=>
  string(19) "2020-03-27 04:08:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8743"
  ["article_id"]=>
  string(4) "8743"
  [1]=>
  string(41) "Ventilator Production Surges at Medtronic"
  ["article_title"]=>
  string(41) "Ventilator Production Surges at Medtronic"
  [2]=>
  string(150) "&#nl        MINNEAPOLIS—To address the global COVID-19 pandemic, Medtronic Inc. has increased ventilator production at its factories.&#nl      "
  ["short_description"]=>
  string(150) "&#nl        MINNEAPOLIS—To address the global COVID-19 pandemic, Medtronic Inc. has increased ventilator production at its factories.&#nl      "
  [3]=>
  string(150) "&#nl        MINNEAPOLIS—To address the global COVID-19 pandemic, Medtronic Inc. has increased ventilator production at its factories.&#nl      "
  ["description"]=>
  string(150) "&#nl        MINNEAPOLIS—To address the global COVID-19 pandemic, Medtronic Inc. has increased ventilator production at its factories.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(84) "https://www.assemblymag.com/articles/95602-ventilator-production-surges-at-medtronic"
  ["blog_url"]=>
  string(84) "https://www.assemblymag.com/articles/95602-ventilator-production-surges-at-medtronic"
  [15]=>
  string(19) "2020-03-27 04:04:00"
  ["add_date"]=>
  string(19) "2020-03-27 04:04:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:24:13"
  ["create_at"]=>
  string(19) "2020-03-31 11:24:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8678"
  ["article_id"]=>
  string(4) "8678"
  [1]=>
  string(62) "Early-Warning System for Detecting Infections Is Being Studied"
  ["article_title"]=>
  string(62) "Early-Warning System for Detecting Infections Is Being Studied"
  [2]=>
  string(153) "&#nlMost of the early physiological and biochemical changes that could be an indication of an infection in a patient’s body are asympto"
  ["short_description"]=>
  string(153) "&#nlMost of the early physiological and biochemical changes that could be an indication of an infection in a patient’s body are asympto"
  [3]=>
  string(5245) "&#nl
Most of the early physiological and biochemical changes that could be an indication of an infection in a patient’s body are asymptomatic, said Ben Hwang, chairman and CEO of Profusa, in an interview with MD+DI. “People don't see or feel [them],” he said, noting that it could be weeks before patients present with symptoms such as a fever or cough. But in the meantime, as we have seen with the COVID-19 pandemic, asymptomatic people could be spreading diseases unknowingly.
&#nl
“What will be helpful is to be able to identify individuals at the presymptomatic stage, so that you could actually create interventional procedures along that population before they are symptomatic, and before they can pass on the disease to somebody else,” Hwang said.
&#nl
He believes that Profusa’s Lumee Oxygen Platform will be able to do this. “The hypothesis is that our sensors could actually pick up those changes before an individual realizes [that he or she] has a fever or a sore throat,” he said.
&#nl
To prove this, Profusa is currently conducting a study, in collaboration with RTI International and research centers including Duke University and Imperial College London, to potentially assist in the early detection of influenza outbreaks. The goal of the study is to develop an early identification system to detect not only disease outbreaks but also biological attacks and pandemics up to three weeks earlier than current methods. The results of the study are anticipated to be available in 2021.
&#nl
In the study, “we are asking these patients to wear our Profusa reader 24 hours a day, seven days a week, so we're continuously gathering information,” Hwang said. “We're keeping track of basic biochemistry biometric markers, such heart rate, breathing, etc. And we know when these subjects are inoculated with a mild form of flu virus, and then we keep track of them in a hospital and clinical setting, from healthy to infection to symptomatic to the recovery stage.”
&#nl
Hwang said that information will then be analyzed. “Our idea then is to be able to take a look at that data and see the tell-tale biochemical signatures that we could actually detect in the asymptomatic stage,” he said. “Once that is figured out and this is calibrated and referenced, then we'll be able to launch this particular application in the market broadly.”
&#nl
There are three components to the Lumee Oxygen Platform. “The first is a small sliver of a material called hydrogel, very similar to a contact lens,” said Hwang. The smart gel is linked to a light-emitting molecule that emits a fluorescent signal in the presence of one or more body chemicals such as oxygen, glucose, lactate, or other biomarker. “The hydrogel material is inserted under the skin into the subcutaneous space via a hypodermic needle injection,” Hwang continued. “And you now have in place inside the body a small little laboratory.”
&#nl
The second component is a reader on the surface of the skin, Hwang said. “Because the sensing molecule is fluorescent, it returns a fluorescent signal and on that same reader there's a photo detector on the surface of the skin that detects that return light signal coming back,” Hwang explained. “If the fluorescent molecule of the hydrogel is bound or unbound to a chemical of interest, the fluorescence changes, and it is those changes in the fluorescent signature that the reader on the surface of the skin can read.”
&#nl
The platform’s third component is the software. “The reader then can take that reading and send it via Bluetooth to a phone or to a tablet,” Hwang said. “And the software program then displays the signal in a way that the physician or individual can make sense of what that number means.”
&#nl
Profusa’s first application of the technology, which is CE marked in Europe, measures dissolved oxygen at the tissue level in the fluid that bathes cells.
&#nl
But Hwang sees this technology being used for many more applications. He said everybody can benefit from having real-time information about their health. “I think it's profound in that way that everybody could actually start leveraging medical-grade technology to make better, more actionable, and more relevant health choices,” he concluded.
"
  ["description"]=>
  string(5245) "&#nl
Most of the early physiological and biochemical changes that could be an indication of an infection in a patient’s body are asymptomatic, said Ben Hwang, chairman and CEO of Profusa, in an interview with MD+DI. “People don't see or feel [them],” he said, noting that it could be weeks before patients present with symptoms such as a fever or cough. But in the meantime, as we have seen with the COVID-19 pandemic, asymptomatic people could be spreading diseases unknowingly.
&#nl
“What will be helpful is to be able to identify individuals at the presymptomatic stage, so that you could actually create interventional procedures along that population before they are symptomatic, and before they can pass on the disease to somebody else,” Hwang said.
&#nl
He believes that Profusa’s Lumee Oxygen Platform will be able to do this. “The hypothesis is that our sensors could actually pick up those changes before an individual realizes [that he or she] has a fever or a sore throat,” he said.
&#nl
To prove this, Profusa is currently conducting a study, in collaboration with RTI International and research centers including Duke University and Imperial College London, to potentially assist in the early detection of influenza outbreaks. The goal of the study is to develop an early identification system to detect not only disease outbreaks but also biological attacks and pandemics up to three weeks earlier than current methods. The results of the study are anticipated to be available in 2021.
&#nl
In the study, “we are asking these patients to wear our Profusa reader 24 hours a day, seven days a week, so we're continuously gathering information,” Hwang said. “We're keeping track of basic biochemistry biometric markers, such heart rate, breathing, etc. And we know when these subjects are inoculated with a mild form of flu virus, and then we keep track of them in a hospital and clinical setting, from healthy to infection to symptomatic to the recovery stage.”
&#nl
Hwang said that information will then be analyzed. “Our idea then is to be able to take a look at that data and see the tell-tale biochemical signatures that we could actually detect in the asymptomatic stage,” he said. “Once that is figured out and this is calibrated and referenced, then we'll be able to launch this particular application in the market broadly.”
&#nl
There are three components to the Lumee Oxygen Platform. “The first is a small sliver of a material called hydrogel, very similar to a contact lens,” said Hwang. The smart gel is linked to a light-emitting molecule that emits a fluorescent signal in the presence of one or more body chemicals such as oxygen, glucose, lactate, or other biomarker. “The hydrogel material is inserted under the skin into the subcutaneous space via a hypodermic needle injection,” Hwang continued. “And you now have in place inside the body a small little laboratory.”
&#nl
The second component is a reader on the surface of the skin, Hwang said. “Because the sensing molecule is fluorescent, it returns a fluorescent signal and on that same reader there's a photo detector on the surface of the skin that detects that return light signal coming back,” Hwang explained. “If the fluorescent molecule of the hydrogel is bound or unbound to a chemical of interest, the fluorescence changes, and it is those changes in the fluorescent signature that the reader on the surface of the skin can read.”
&#nl
The platform’s third component is the software. “The reader then can take that reading and send it via Bluetooth to a phone or to a tablet,” Hwang said. “And the software program then displays the signal in a way that the physician or individual can make sense of what that number means.”
&#nl
Profusa’s first application of the technology, which is CE marked in Europe, measures dissolved oxygen at the tissue level in the fluid that bathes cells.
&#nl
But Hwang sees this technology being used for many more applications. He said everybody can benefit from having real-time information about their health. “I think it's profound in that way that everybody could actually start leveraging medical-grade technology to make better, more actionable, and more relevant health choices,” he concluded.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(82) "https://www.mddionline.com/early-warning-system-detecting-infections-being-studied"
  ["blog_url"]=>
  string(82) "https://www.mddionline.com/early-warning-system-detecting-infections-being-studied"
  [15]=>
  string(19) "2020-03-27 03:15:35"
  ["add_date"]=>
  string(19) "2020-03-27 03:15:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:39"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8520"
  ["article_id"]=>
  string(4) "8520"
  [1]=>
  string(67) "Gilead Backs Down on Special Designation for Possible COVID-19 Drug"
  ["article_title"]=>
  string(67) "Gilead Backs Down on Special Designation for Possible COVID-19 Drug"
  [2]=>
  string(150) "THURSDAY, March 26, 2020 -- Following severe criticism, Gilead Sciences is backing off special designation of its antiviral drug remdesivir -- which s"
  ["short_description"]=>
  string(150) "THURSDAY, March 26, 2020 -- Following severe criticism, Gilead Sciences is backing off special designation of its antiviral drug remdesivir -- which s"
  [3]=>
  string(246) "THURSDAY, March 26, 2020 -- Following severe criticism, Gilead Sciences is backing off special designation of its antiviral drug remdesivir -- which shows promise against COVID-19 -- that would have allowed the company to block competition and..."
  ["description"]=>
  string(246) "THURSDAY, March 26, 2020 -- Following severe criticism, Gilead Sciences is backing off special designation of its antiviral drug remdesivir -- which shows promise against COVID-19 -- that would have allowed the company to block competition and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(204) "https://www.drugs.com/news/gilead-backs-down-special-designation-possible-covid-19-89223.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Backs+Down+on+Special+Designation+for+Possible+COVID-19+Drug"
  ["blog_url"]=>
  string(204) "https://www.drugs.com/news/gilead-backs-down-special-designation-possible-covid-19-89223.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Backs+Down+on+Special+Designation+for+Possible+COVID-19+Drug"
  [15]=>
  string(19) "2020-03-27 03:03:25"
  ["add_date"]=>
  string(19) "2020-03-27 03:03:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:17:59"
  ["create_at"]=>
  string(19) "2020-03-31 11:17:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}